Indivior to end Reckitt supply deal in Jan 2027

Q: Has INDV secured a new supplier for SUBOXONE and SUBUTEX tablets?

Indivior states it has identified a new supplier. Its obligations under the new supply agreement will become enforceable only after validation of the new supplier’s manufacturing process, and this agreement is stated as not expected to be material to Indivior Pharmaceuticals, Inc.

Q: What costs will INDV pay to Reckitt Benckiser under the Deed of Variation and Termination?

Indivior agreed to pay certain costs to Reckitt Benckiser, including costs from ordering lower volumes than contemplated, asset disposal and depreciation recovery costs, redundancy costs, incentive costs, and potential third‑party costs. The aggregate of these costs is fixed or capped and stated as not material to the registrant.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Indivior Pharmaceuticals, Inc. (INDV) reports that its subsidiary Indivior UK Limited and Reckitt Benckiser Healthcare (UK) Limited signed a Deed of Variation and Termination on September 9, 2026 to accelerate termination of their Copacker Supply Agreement for SUBOXONE and SUBUTEX tablets to January 15, 2027. The Copacker Supply Agreement will remain in effect until that accelerated termination date.

Indivior has identified a new supplier, and its obligations under the new supply agreement will only become enforceable after validation of the new supplier’s manufacturing process; this new agreement is stated as not expected to be material to Indivior Pharmaceuticals, Inc. Under the Deed of Variation and Termination, Reckitt Benckiser will manufacture additional units before the new termination date, and Indivior will pay certain specified costs, including lower-volume, asset disposal, depreciation recovery, redundancy, incentive and potential third-party costs. The aggregate amount of these costs is fixed or capped and is stated as not material to the registrant.

8-K Event Classification

2 items: 1.02, 9.01

2 items

Item 1.02 Termination of a Material Definitive Agreement Business

A significant contract was terminated, which may affect business operations or revenue.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Deed of Variation and Termination date: September 9, 2026 Accelerated termination date: January 15, 2027 Exhibit 10.1: Deed of Variation and Termination +1 more

4 metrics

Deed of Variation and Termination date September 9, 2026 Date Indivior UK Limited and Reckitt Benckiser executed the Deed of Variation and Termination

Accelerated termination date January 15, 2027 New termination date for the Copacker Supply Agreement for SUBOXONE and SUBUTEX tablets

Exhibit 10.1 Deed of Variation and Termination Filed as an exhibit effective September 9, 2026 between Indivior UK Limited and Reckitt Benckiser Healthcare (UK) Limited

Exhibit 104 Cover Page Interactive Data File Inline XBRL cover page data file referenced in the report

Key Terms

Deed of Variation and Termination, Copacker Supply Agreement, redundancy costs, asset disposal and depreciation recovery costs, +1 more

5 terms

Deed of Variation and Termination regulatory

"entered into a Deed of Variation and Termination relating to that certain Copacker"

Copacker Supply Agreement financial

"relating to that certain Copacker Supply Agreement dated December 23, 2014"

redundancy costs financial

"certain asset disposal and depreciation recovery costs, certain redundancy costs, certain"

asset disposal and depreciation recovery costs financial

"including costs resulting from Indivior ordering lower volumes from RB than contemplated"

emerging growth company regulatory

"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What agreement did INDV terminate with Reckitt Benckiser?

Indivior UK Limited and Reckitt Benckiser Healthcare (UK) Limited executed a Deed of Variation and Termination to end their Copacker Supply Agreement under which Reckitt Benckiser manufactured SUBOXONE and SUBUTEX tablets for Indivior. The agreement’s termination date was accelerated to January 15, 2027.

When will the Copacker Supply Agreement for INDV’s SUBOXONE and SUBUTEX now end?

The Copacker Supply Agreement’s termination date has been accelerated to January 15, 2027. Until that date, the agreement, as amended by the Deed of Variation and Termination signed on September 9, 2026, will remain in effect.

Has INDV secured a new supplier for SUBOXONE and SUBUTEX tablets?

Indivior states it has identified a new supplier. Its obligations under the new supply agreement will become enforceable only after validation of the new supplier’s manufacturing process, and this agreement is stated as not expected to be material to Indivior Pharmaceuticals, Inc.

What costs will INDV pay to Reckitt Benckiser under the Deed of Variation and Termination?

Indivior agreed to pay certain costs to Reckitt Benckiser, including costs from ordering lower volumes than contemplated, asset disposal and depreciation recovery costs, redundancy costs, incentive costs, and potential third‑party costs. The aggregate of these costs is fixed or capped and stated as not material to the registrant.

Is the termination and transition expected to be material to INDV?

Indivior states that its agreement with the new supplier is not expected to be material to Indivior Pharmaceuticals, Inc., and that the aggregate amount of costs owed to Reckitt Benckiser under the Deed of Variation and Termination will not be material to the registrant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/15/2026 - 04:29 PM Accepted by SEC EDGAR 09/15/2026 - 04:28 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 9, 2026

INDIVIOR PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)


Delaware	001-37835	41-2520873
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)


10710 Midlothian Turnpike, Suite 125 North Chesterfield, VA						23235
(Address of principal executive offices)						(Zip Code)

Registrant’s telephone number, including area code: 804-379-1090


not applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, $0.001 par value per share

INDV

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

Item 1.02 Termination of a Material Definitive Agreement.

On September 9, 2026, Indivior UK Limited ("Indivior") and Reckitt Benckiser Healthcare (UK) Limited ("RB") entered into a Deed of Variation and Termination relating to that certain Copacker Supply Agreement dated December 23, 2014, as was amended on March 29, 2019 (the "Copacker Supply Agreement"). RB manufactures SUBOXONE® Tablets and SUBUTEX® Tablets for Indivior pursuant to the terms of the Copacker Supply Agreement. Pursuant to the Deed of Variation and Termination, the parties agreed to accelerate the termination date of the Copacker Supply Agreement to January 15, 2027. The Copacker Supply Agreement, as amended by the Deed of Variation and Termination, will remain in effect until the accelerated termination date. Indivior has identified a new supplier. Indivior's obligations under its agreement with its new supplier will become enforceable against it only after validation of the new supplier's manufacturing process, and this agreement is not expected to be material to Indivior Pharmaceuticals, Inc. (the “Registrant”).

Pursuant to the Deed of Variation and Termination, (i) RB has agreed to manufacture additional units prior to the new termination date, and (ii) Indivior has agreed to pay certain costs to RB including costs resulting from Indivior ordering lower volumes from RB than contemplated by the Copacker Supply Agreement, certain asset disposal and depreciation recovery costs, certain redundancy costs, certain incentive costs, and potential third party costs. The aggregate amount of such costs are fixed or capped and will not be material to the Registrant.

The foregoing description of the Deed of Variation and Termination is qualified in its entirety by reference to the full text of the Deed of Variation and Termination which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.						Description
10.1						Deed of Variation and Termination effective September 9, 2026 between Indivior UK Limited and Reckitt Benckiser Healthcare (UK) Limited.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



		Indivior Pharmaceuticals, Inc.

Date: September 15, 2026	By:	/s/ Ryan Preblick
		Name: Ryan Preblick
		Title: Chief Financial Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

EX-10.1 EX-10.1 64.6 KB

Indivior to end Reckitt supply deal in Jan 2027

Rhea-AI Filing Summary

Positive

Negative